12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Portfolio Pulse from Benzinga Insights
In Tuesday's pre-market session, several healthcare stocks showed significant movement. Acrivon Therapeutics, Biophytis, MyMD Pharmaceuticals, Addex Therapeutics, Brainstorm Cell, and Inspire Veterinary were among the gainers, with Acrivon Therapeutics leading with a 72.3% increase. On the downside, Vincerx Pharma, BioSig Technologies, Neogen, Tilray Brands, YS Biopharma Co, and Etao International Co experienced declines, with Vincerx Pharma dropping by 64.7%. Notably, Inspire Veterinary, Neogen, and Tilray Brands released their earnings reports.
April 09, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Neogen shares declined by 16.63% to $11.99, coinciding with the release of their Q3 earnings.
The decline in NEOG's stock price following its earnings release suggests the financial results did not meet investor expectations.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Tilray Brands stock decreased by 15.45% to $2.19 after their Q3 earnings were announced.
The negative reaction to Tilray Brands' Q3 earnings report indicates disappointing results or outlook, impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
Vincerx Pharma experienced the largest decline among the mentioned stocks, dropping 64.7% to $1.69.
The sharp decline in VINC's stock price suggests negative news or investor sentiment, significantly impacting its market value.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Acrivon Therapeutics stock surged 72.3% to $10.19, leading the gainers in Tuesday's pre-market session.
The significant surge in ACRV's stock price indicates strong investor interest, likely due to positive developments or expectations.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100
POSITIVE IMPACT
Inspire Veterinary shares rose 20.64% to $0.06, following the release of their Q4 earnings.
The positive movement in IVP's stock price post-earnings release indicates a favorable investor response to the financial results.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 90